Rat igg2a isotype control antibody

Manufactured by BioXCell

Sourced in United States

The Rat IgG2a isotype control antibody is a laboratory reagent used as a control in immunoassays and other experiments. It serves as a reference point to help determine the specificity of primary antibodies in samples.

Automatically generated - may contain errors

Lab products found in correlation

Rat anti mouse gr 1 ly6g ly6c, by BioXCell (2 mentions) Be0004 1, by BioXCell (2 mentions) Be0164, by BioXCell (2 mentions) Clodronate, by Encapsula Nanosciences (1 mentions) Anti ly6g antibody, by BioXCell (1 mentions) Clone 1a8, by BioXCell (1 mentions) Pd l1, by BioXCell (1 mentions) Celecoxib, by Selleck Chemicals (1 mentions)

9 protocols using rat igg2a isotype control antibody

Systemic PMN/MDSC Depletion Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were injected i.p. with either 200 μg rat anti-mouse Gr-1 (Ly6G/Ly6C), Ly6G, or rat IgG2A isotype control antibodies (Bio-X-Cell, Lebanon, NH) in 200 μl sterile PBS to systemically deplete PMNs/MDSCs 48 h prior to and 2 h after lethal challenge with Ca/Sa (i.p.) or Ca alone (i.v.). Injections were given every 2 days for the duration of the study. Depletion was confirmed by flow cytometry (Fig. S2).

Lilly E.A., Bender B.E., Esher Righi S., Fidel PL J.r, & Noverr M.C. (2021). Trained Innate Immunity Induced by Vaccination with Low-Virulence Candida Species Mediates Protection against Several Forms of Fungal Sepsis via Ly6G+ Gr-1+ Leukocytes. mBio, 12(5), e02548-21.

+ Open protocol

+ Expand

Selective Depletion of Neutrophils

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were injected i.p. with either 200 μg rat anti-mouse Gr-1 (Ly6G/Ly6C) or rat IgG2A isotype control antibodies (Bio-X-Cell) in 200 µl sterile PBS to systemically deplete PMNLs 48 h prior to and 2 h after rechallenge with C. albicans and S. aureus. Injections were given every 2 days for the duration of the study. Depletion was confirmed by flow cytometry.

Lilly E.A., Ikeh M., Nash E.E., Fidel PL J.r, & Noverr M.C. (2018). Immune Protection against Lethal Fungal-Bacterial Intra-Abdominal Infections. mBio, 9(1), e01472-17.

+ Open protocol

+ Expand

Macrophage and Granulocyte Depletion for Sepsis

Check if the same lab product or an alternative is used in the 5 most similar protocols

For macrophage depletion, liposome-encapsulated clodronate and liposome vehicle (1 mg/mouse; Encapsula NanoSciences) were injected i.p. in 200 µl 1 day prior to sepsis challenge. clodronate (dichloromethylene-bisphosphonate) is encapsulated in the aqueous compartments of liposomes which have been filtered for size to remove larger particles that might be toxic to animals. The liposomal solution is injected intraperitoneally into the mice where phagocytic cells recognize the liposomes as foreign particles and phagocytose them. When internalized, the liposomes release clodronate into the cytosol, resulting in cell death. Liposomes without clodronate exhibit no cellular toxicity.
For granulocyte depletion, mice were injected i.p. with either 200 μg rat anti-mouse Gr-1⁺ (Ly6G/Ly6C) or rat IgG2A isotype control antibodies (Bio-X-Cell) in 200 µl sterile non-pyrogenic PBS to systemically deplete PMNLs 48 h prior to and 2 h after challenge. Injections were given every 2 days for the duration of the study. Depletion was confirmed by flow cytometry.

Harriett A.J., Esher Righi S., Lilly E.A., Fidel P J.r, & Noverr M.C. (2022). Efficacy of Candida dubliniensis and Fungal β-Glucans in Inducing Trained Innate Immune Protection Against Inducers of Sepsis. Frontiers in Cellular and Infection Microbiology, 12, 898030.

+ Open protocol

+ Expand

Neutrophil Depletion for Influenza

Check if the same lab product or an alternative is used in the 5 most similar protocols

For in vivo neutrophil depletion, 150 μg anti‐Ly6G antibody (BioXCell, Clone 1A8) or rat IgG2a isotype control antibody (BioXCell) was administered in 100 μl volume intravenously by tail vein injection. Treatment was given from day 5 post‐influenza infection and every 24 h thereafter. Up to 70% depletion was confirmed by staining and enumeration of CD45⁺CD11b⁺Ly6C^mid cells, while binding of blocking antibody to remaining neutrophils was observed by negative staining to Ly6G antibody (Fig EV5A), as assessed by flow cytometry.

Er J.Z., Koean R.A, & Ding J.L. (2018). Loss of T‐bet confers survival advantage to influenza–bacterial superinfection. The EMBO Journal, 38(1), e99176.

+ Open protocol

+ Expand

CD8+ T-cell Depletion Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The T-cell depletion protocol was performed as previously described with minor modifications. Anti-CD8 (clone: 53-6.7, Cat. No. BE0004-1, Bio X Cell, Lebanon, NH, U.S. A) (200 μg per mouse) or rat IgG2a isotype control antibody (clone: 2A3, Cat. No. BE0089; Bio X Cell) was intraperitoneally injected into mice on Days 10 and 15. Approximately 90% of CD8⁺ T cells were depleted, as determined by flow cytometry analysis.

Li C.Y., Anuraga G., Chang C.P., Weng T.Y., Hsu H.P., Ta H.D., Su P.F., Chiu P.H., Yang S.J., Chen F.W., Ye P.H., Wang C.Y, & Lai M.D. (2023). Repurposing nitric oxide donating drugs in cancer therapy through immune modulation. Journal of Experimental & Clinical Cancer Research : CR, 42, 22.

+ Open protocol

+ Expand

Ibrutinib and PD-1/PD-L1 Blockade in CLL

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two to three weeks after tumor cell transplantation, tumor load in blood (defined as the number of CD5⁺CD19⁺ CLL cells/L) was measured, and mice were assigned to different treatment arms to achieve comparable tumor load in all groups at baseline prior to treatment. Ibrutinib (provided by Pharmacyclics LLC, an AbbVie Company) was administered in drinking water containing sterile control vehicle (1% HP--CD) at a concentration of 0.16 mg/mL, as previously described.^{26 (link)} For PD-1/PD-L1 blockade, mice were injected i.p. with 0.2 mg of PD-1 (clone: RMP1-14), PD-L1 (clone: 10F.9G2), or rat IgG2a isotype control antibody (clone: 2A3; all from BioXcell, West Lebanon, NH, USA) every 3 days for 4 weeks.

Hanna B.S., Yazdanparast H., Demerdash Y., Roessner P.M., Schulz R., Lichter P., Stilgenbauer S, & Seiffert M. (2020). Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in E-TCL1 mice. Haematologica, 106(4), 968-977.

+ Open protocol

+ Expand

Modulating CEBPA for Tumor Immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

MTL-CEBPA, a liposomal nanoparticle encapsulating a small activating RNA (saRNA) for C/EBPa (CEBPA-51), and its control liposomal nanoparticle with a non-specific oligonucleotide (NOV-FLUC) encapsulating siFLUC were supplied by MiNA Therapeutics Ltd, London, United Kingdom. MTL-CEBPA or NOV-FLUC was intravenously injected to the tumor-bearing mice twice per week at 3 mg/kg. For the T cell depletion study, intraperitoneal injection with 100 μg of anti-mouse CD8a antibody (BioXcell, BE0004-1) or rat IgG2a isotype control antibody (BioXcell) was started 2 days before tumor injection and repeated twice a week for 2 weeks. Anti-mouse CTLA-4 antibody (BioXcell, BE0164) or mouse IgG2b isotype control antibody was intraperitoneally injected to the tumor-bearing mice 100 μg per mouse on Days 10, 17 and 24. Celecoxib, selective cox2 inhibitor (Selleck Chemicals) was suspended in 0.5% methylcellulose and orally treated at 50 mg/kg to the tumor-bearing mice every day. Lipofermata was dissolved in DMSO and diluted in 30% (v/v) Kolliphor, and then subcutaneously injected to the tumor-bearing mice at 2 mg/kg twice a day.

Hashimoto A., Sarker D., Reebye V., Jarvis S., Sodergren M.H., Kossenkov A., Sanseviero E., Raulf N., Vasara J., Andrikakou P., Meyer T., Huang K.W., Plummer R., Chee C.E., Spalding D., Pai M., Khan S., Pinato D.J., Sharma R., Basu B., Palmer D., Ma Y.T., Evans J., Habib R., Martirosyan A., Elasri N., Reynaud A., Rossi J.J., Cobbold M., Habib N.A, & Gabrilovich D.I. (2021). Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. Clinical Cancer Research, 27(21), 5961-5978.

+ Open protocol

+ Expand

Murine Melanoma Tumor Growth Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were anesthetized with Avertin (2.5%), shaved at the injection site, and then injected in the flank subcutaneously with 250,000 or 500,000 B16-F10 (scramble, LSD1 KO, MDA5 KO, IFN-β KO, LSD1/MDA5 DKO and LSD1/IFN-β DKO), or 250,000 or 500,000 D4m.3A (scramble and LSD1 KO) tumor cells. Tumors were measured every 2–3 days once palpable (long diameter and short diameter) with a caliper. Tumor volume was determined using the volume formula for an ellipsoid: 1/2 × D × d² where D is the longer diameter and d is the shorter diameter. Mice were sacrificed when tumors reached 2000 mm³ or upon ulceration/bleeding.
For antibody treatments, mice were given 100 µg antibody via intraperitoneal injection at day 14, 16, 18, and 20 post tumor injection using the following antibodies: anti-PD-1 (clone 29F.1A12) or isotype (clone 2A3) (Liang et al., 2003 (link)). Rat IgG2a isotype control antibody was purchased from BioXCell (cat#BE0089). Prior to treatments mice were randomized such that treatment groups had similar average tumor volumes prior to treatment initiation.

Sheng W., LaFleur M.W., Nguyen T.H., Chen S., Chakravarthy A., Conway J.R., Li Y., Chen H., Yang H., Hsu P.H., Van Allen E.M., Freeman G.J., De Carvalho D.D., He H.H., Sharpe A.H, & Shi Y. (2018). LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell, 174(3), 549-563.e19.

+ Open protocol

+ Expand

Nanoparticle-Mediated CEBPA Upregulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

MTL-CEBPA, a liposomal nanoparticle encapsulating a saRNA for CEBPA (CEBPA-51), and its control liposomal nanoparticle with a nonspecific oligonucleotide (NOV-FLUC) encapsulating siFLUC were supplied by MiNA Therapeutics Ltd. MTL-CEBPA or NOV-FLUC was intravenously injected into the tumor-bearing mice twice per week at 3 mg/kg. For the T-cell depletion study, intraperitoneal injection with 100 μg of anti-mouse CD8a antibody (Bio X Cell, BE0004-1) or rat IgG2a isotype control antibody (Bio X Cell) was started 2 days before tumor injection and repeated twice a week for 2 weeks. Anti-mouse CTLA-4 antibody (Bio X Cell, BE0164) or mouse IgG2b isotype control antibody was intraperitoneally injected into the tumor-bearing mice: 100 μg per mouse on days 10, 17, and 24. Celecoxib, a selective cox2 inhibitor (Selleck Chemicals), was suspended in 0.5% methylcellulose and orally treated at 50 mg/kg to the tumor-bearing mice every day. Lipofermata was dissolved in DMSO and diluted in 30% (v/v) Kolliphor, and then subcutaneously injected into the tumor-bearing mice at 2 mg/kg twice a day.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!